CY1124822T1 - Στρωματοποιημενοι και ελεγχομενης αποδεσμευσης συνθετοι φορεις εγκλεισμου κυκλοδεξτρινης - Google Patents

Στρωματοποιημενοι και ελεγχομενης αποδεσμευσης συνθετοι φορεις εγκλεισμου κυκλοδεξτρινης

Info

Publication number
CY1124822T1
CY1124822T1 CY20211100632T CY211100632T CY1124822T1 CY 1124822 T1 CY1124822 T1 CY 1124822T1 CY 20211100632 T CY20211100632 T CY 20211100632T CY 211100632 T CY211100632 T CY 211100632T CY 1124822 T1 CY1124822 T1 CY 1124822T1
Authority
CY
Cyprus
Prior art keywords
cyclodextrin
layered
controlled release
complex
ingredients
Prior art date
Application number
CY20211100632T
Other languages
English (en)
Inventor
Al Czap
Original Assignee
Czap Research And Development, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/232,647 external-priority patent/US20170224841A1/en
Priority claimed from US15/285,264 external-priority patent/US20170224842A1/en
Application filed by Czap Research And Development, Llc filed Critical Czap Research And Development, Llc
Publication of CY1124822T1 publication Critical patent/CY1124822T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C12N9/1074—Cyclomaltodextrin glucanotransferase (2.4.1.19)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/50—Polysaccharides, gums
    • A23V2250/51—Polysaccharide
    • A23V2250/5112—Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01054—Cyclomaltodextrinase (3.2.1.54), i.e. cyclodextrinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)

Abstract

Η εφεύρεση παρέχει φορείς χορήγησης συμπλόκου κυκλοδεξτρίνης, στους οποίους το σύμπλοκο εγκλεισμού κυκλοδεξτρίνης παρέχεται μαζί με ένζυμο που έχει δραστικότητα αποικοδόμησης κυκλοδεξτρίνης ικανή να αφομοιώσει την κυκλοδεξτρίνη, έτσι ώστε κατά την χορήγηση του φορές σε έναν στόχο το ένζυμο να ενεργοποιείται και να απελευθερώνει το φιλοξενούμενο μόριο από την μήτρα κυκλοδεξτρίνης. Σε εναλλακτικές πτυχές, αυτοί οι φορείς χορήγησης σύνθετης κυκλοδεξτρίνης παρέχονται για παράδειγμα με τη μορφή φαρμάκων, συστατικών τροφίμων, συστατικών ιατρικών τροφίμων, συστατικών συμπληρωμάτων διατροφής, συστατικών συμπληρώματος διατροφής, ζιζανιοκτόνων, εντομοκτόνων, μυκητοκτόνων, απωθητικών ζώων, φερομονών, ρυθμιστών ανάπτυξης φυτών, αρώματα, υφάσματα ή υλικά συσκευασίας.
CY20211100632T 2016-02-04 2021-07-13 Στρωματοποιημενοι και ελεγχομενης αποδεσμευσης συνθετοι φορεις εγκλεισμου κυκλοδεξτρινης CY1124822T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662291202P 2016-02-04 2016-02-04
US15/232,647 US20170224841A1 (en) 2016-02-04 2016-08-09 Controlled-release and stratified cyclodextrin inclusion complex vehicles
US15/285,264 US20170224842A1 (en) 2016-02-04 2016-10-04 Controlled-release and stratified cyclodextrin inclusion complex vehicles
US201762444036P 2017-01-09 2017-01-09
PCT/US2017/016583 WO2017136775A1 (en) 2016-02-04 2017-02-03 Controlled-release and stratified cyclodextrin inclusion complex vehicles

Publications (1)

Publication Number Publication Date
CY1124822T1 true CY1124822T1 (el) 2022-11-25

Family

ID=59500049

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100632T CY1124822T1 (el) 2016-02-04 2021-07-13 Στρωματοποιημενοι και ελεγχομενης αποδεσμευσης συνθετοι φορεις εγκλεισμου κυκλοδεξτρινης

Country Status (18)

Country Link
US (2) US11633448B2 (el)
EP (3) EP4098282A1 (el)
JP (3) JP6884420B2 (el)
KR (1) KR20190005823A (el)
CN (2) CN115154619A (el)
AU (3) AU2017214669B2 (el)
CA (1) CA3012837A1 (el)
CY (1) CY1124822T1 (el)
DK (1) DK3411047T3 (el)
ES (1) ES2878580T3 (el)
HR (1) HRP20211086T1 (el)
HU (1) HUE055157T2 (el)
LT (1) LT3411047T (el)
PL (1) PL3411047T3 (el)
PT (1) PT3411047T (el)
RS (1) RS62097B1 (el)
SI (1) SI3411047T1 (el)
WO (1) WO2017136775A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115154619A (zh) * 2016-02-04 2022-10-11 西泽普研究与发展有限责任公司 受控释放和层状的环糊精包合物媒介物
JP7181185B2 (ja) * 2016-09-16 2022-11-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤
EP3810168A1 (en) * 2018-06-20 2021-04-28 Axcella Health Inc. Methods of manufacturing amino acid compositions
CN111183989A (zh) * 2018-11-14 2020-05-22 北京中以新农高科商务咨询有限公司 包含胶囊化挥发性精油和溶解在其中的聚合物的农用制剂
KR102200694B1 (ko) * 2018-11-29 2021-01-08 한국세라믹기술원 소수성 활성성분의 안정화 방법 및 안정화된 활성성분을 함유하는 화장료 조성물
WO2020168421A1 (en) * 2019-02-19 2020-08-27 Agrima Scientific Corp. Cyclodextrin inclusion complexes of cannabis extracts
CN110123876A (zh) * 2019-05-30 2019-08-16 汉义生物科技（北京）有限公司 一种含有非精神活性大麻素的包合物及其制备方法
CN115335040A (zh) * 2020-03-23 2022-11-11 西泽普研究与发展有限责任公司 口服萜烯环糊精包合物媒介物
CN111298108A (zh) * 2020-04-10 2020-06-19 亘元(天津)生物医药科技有限公司 一种儿童长效型复合酶消毒组合物及应用
WO2021257626A1 (en) * 2020-06-15 2021-12-23 Nanosynthons Llc Excipients providing stabilization and enhanced water solubilization and their uses
CN116437816A (zh) * 2020-11-17 2023-07-14 德乐有限公司 用于选择性分离至少一种具有至少一个非极性基团的有机物质的方法，以及所述物质在食品、享乐品、化妆品或医药产品中的用途
WO2022202904A1 (ja) 2021-03-25 2022-09-29 株式会社シクロケムバイオ 腸管機能向上剤
KR102707423B1 (ko) * 2021-11-05 2024-09-19 농업회사법인 주식회사 아그로비즈 농가의 야생동물 및 해충 퇴치를 위한 복합 기능의 방제키트
IT202200008894A1 (it) * 2022-05-03 2023-11-03 Biodue S P A Composizione nutriceutica comprendente citicolina, vitamina D3 e olio di canapa.
CN115039742B (zh) * 2022-05-24 2023-08-29 江苏宁录科技股份有限公司 一种草地贪夜蛾性信息素双重缓释诱芯及其制备方法
WO2024127024A1 (en) * 2022-12-16 2024-06-20 Kingdom Therapeutics Limited Cannabinoid based therapy
CN117771389A (zh) * 2023-12-28 2024-03-29 浙江圣达生物药业股份有限公司 L-5-甲基四氢叶酸钙-γ-环糊精包合物及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2453829C2 (de) 1974-11-13 1983-04-07 Siemens AG, 1000 Berlin und 8000 München Verfahren zur Herstellung von Additiven und ihre Verwendung als Glanzbildner
HU176215B (en) * 1978-01-27 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
EP0056995B1 (en) 1981-01-23 1986-03-26 The Wellcome Foundation Limited Chemical complex
JPS5944318A (ja) * 1982-09-04 1984-03-12 Riken Kagaku Kogyo Kk サイクロデキストリン難脱包接物質よりの脱包接法
US4538920A (en) 1983-03-03 1985-09-03 Minnesota Mining And Manufacturing Company Static mixing device
JPH0819004B2 (ja) 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
CA1321192C (en) 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
CA2013485C (en) 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
DE839528T1 (de) * 1996-10-29 1998-10-22 Staroil Ltd Mundlösliche Zusammensetzungen die N-Acetylcystein und Cyclodextrin enthalten
US6065645A (en) 1997-04-01 2000-05-23 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
CN1176784A (zh) * 1997-07-24 1998-03-25 北京路德有限责任公司 对乙酰氨基酚咀嚼片的制造方法及其产品
DE19911097A1 (de) * 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
WO2002044350A2 (de) * 2000-11-28 2002-06-06 Henkel Kommanditgesellschaft Auf Aktien Cyclodextrin-glucanotransferase (cg tase) aus bicillus agaradherens (dsm 9948) sowie wasch- und reinigungsmittel mit dieser neuen cyclodextrin-glucanotransferase
US6566401B2 (en) 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
FI113340B (fi) * 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit
US7001893B2 (en) 2002-10-28 2006-02-21 Council Of Scientific And Industrial Research Inclusion complex of Rifampicin, an anti-tubercular drug, with β-cyclodextrin or 2-hydroxypropyl β-cyclodextrin and a process thereof
KR100675081B1 (ko) * 2003-03-06 2007-01-26 주식회사 서울제약 아세틸시스테인 함유 경구용 제제
WO2006058153A1 (en) 2004-11-23 2006-06-01 Smith & Nephew, Inc. Composite mixer
JP2008546386A (ja) 2005-06-13 2008-12-25 カーギル インコーポレイテッド シクロデキストリン包接複合体及びその製造方法
US20070003528A1 (en) 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
ATE443007T1 (de) 2005-07-22 2009-10-15 Dentaco Gmbh Mehrkammerausgabevorrichtung
US20070072146A1 (en) 2005-09-29 2007-03-29 Dentsply Research And Development Corp. Dispensing syringe having multiple barrels for discharging a dental composition
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US8100295B2 (en) 2006-03-24 2012-01-24 Medmix Systems Ag Dispensing assembly with removably attachable accessories
CN100411688C (zh) 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
JP2010505938A (ja) * 2006-10-13 2010-02-25 ファイザー・リミテッド 家畜動物用の同化剤として有用な複素環式化合物
DK2178521T3 (da) 2007-07-11 2014-04-28 Fertin Pharma As Stabilt medicinsk tyggegummi omfattende cyclodextrin-inklusionskompleks
KR100929920B1 (ko) 2007-09-05 2009-12-04 주식회사 마크로케어 사이클로덱스트린 및 이의 유도체에 소수성 생리활성성분이 포접된 포접체의 제조방법 및 이로써 제조된포접체의 용도
JP2011528400A (ja) * 2008-07-17 2011-11-17 ハーキュリーズ・インコーポレーテッド 水系コーティング組成物を調整する方法
CN105687177A (zh) * 2009-07-15 2016-06-22 小利兰·斯坦福大学托管委员会 N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法
US20150217896A1 (en) 2010-02-11 2015-08-06 Clemson University Packaging materials derived from renewable resources and including a cyclodextrin inclusion complex
EP2444336B1 (de) 2010-10-21 2013-08-28 Sulzer Mixpac AG Doppel-Austragsvorrichtung
CN102058536A (zh) * 2011-01-14 2011-05-18 四川大学 槲皮素羟丙基β－环糊精包和物脂质体及其制备方法和用途
GB2492284B (en) 2011-03-27 2013-07-17 Cellresin Tech Llc Cyclodextrin compositions, articles, and methods
US20140315780A1 (en) 2011-05-05 2014-10-23 Jas Pal Singh Badyal Product
KR101794242B1 (ko) 2011-06-07 2017-11-07 임병갑 서방성 경구용 액상 제제
JP6052175B2 (ja) * 2011-08-02 2016-12-27 小野薬品工業株式会社 左室拡張機能改善剤
US9545393B2 (en) 2012-08-24 2017-01-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating pain
EP3656371A1 (en) 2012-10-02 2020-05-27 Allergan, Inc. Dermal filler hydrogels with vitamin a/cyclodextrin inclusion complexes
KR102411834B1 (ko) 2014-06-04 2022-06-21 프로토키네틱스 인코포레이티드 이식 결과 개선 및 췌장 세포 건강, 생존 향상을 위한 항-노화 글리코펩타이드들의 용도
US9421793B2 (en) 2014-06-26 2016-08-23 Cellresin Technologies, Llc Electrostatic printing of cyclodextrin compositions
US10098964B2 (en) * 2015-03-12 2018-10-16 The Board Of Trustees Of The University Of Illinois Inclusion complexes and methods for making the same
CN115154619A (zh) * 2016-02-04 2022-10-11 西泽普研究与发展有限责任公司 受控释放和层状的环糊精包合物媒介物
US20170224842A1 (en) 2016-02-04 2017-08-10 Czap Research And Development, Llc Controlled-release and stratified cyclodextrin inclusion complex vehicles

Also Published As

Publication number Publication date
AU2017214669B2 (en) 2022-01-13
EP3411047B1 (en) 2021-04-14
HUE055157T2 (hu) 2021-11-29
EP4098282A1 (en) 2022-12-07
JP2022173261A (ja) 2022-11-18
KR20190005823A (ko) 2019-01-16
LT3411047T (lt) 2021-07-26
RS62097B1 (sr) 2021-08-31
JP2021120386A (ja) 2021-08-19
WO2017136775A1 (en) 2017-08-10
PT3411047T (pt) 2021-07-06
JP2019512019A (ja) 2019-05-09
EP3411047A1 (en) 2018-12-12
BR112018016066A2 (pt) 2019-01-02
AU2024219899A1 (en) 2024-10-10
US20230405074A1 (en) 2023-12-21
EP3892303B1 (en) 2023-06-07
JP6884420B2 (ja) 2021-06-09
CN115154619A (zh) 2022-10-11
AU2017214669A1 (en) 2018-08-23
ES2878580T3 (es) 2021-11-19
PL3411047T3 (pl) 2021-11-15
AU2022200988A1 (en) 2022-03-03
SI3411047T1 (sl) 2021-09-30
DK3411047T3 (da) 2021-06-28
US20220257690A1 (en) 2022-08-18
HRP20211086T1 (hr) 2021-10-15
CN108883125B (zh) 2022-08-09
EP3411047A4 (en) 2019-08-28
AU2022200988B2 (en) 2024-06-20
US11633448B2 (en) 2023-04-25
EP3892303A1 (en) 2021-10-13
EP3892303C0 (en) 2023-06-07
CA3012837A1 (en) 2017-08-10
JP7144087B2 (ja) 2022-09-29
CN108883125A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
CY1124822T1 (el) Στρωματοποιημενοι και ελεγχομενης αποδεσμευσης συνθετοι φορεις εγκλεισμου κυκλοδεξτρινης
CO2018005382A2 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
CO2018005384A2 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
PE20240726A1 (es) Composiciones de bacillus thuringiensis rti545
CL2019000109A1 (es) Proteínas quiméricas insecticidas, composiciones que las comprenden, y estrategias para el control de plagas de lepidópteros basadas en su uso.(divisional solicitud 201700895).
CY1118712T1 (el) Συνδυασμοι δραστικων συστατικων με εντομοκτονους και ακαρεοκτονους ιδιοτητες
GT201600198A (es) Combinaciones de principios activos insecticidas y nematocidas
CY1118622T1 (el) Παρασιτοκτονικες συνθεσεις που περιλαμβανουν πολλαπλους δραστικους παραγοντες, μεθοδοι και χρησεις αυτων
BR112012026360A2 (pt) material polimérico contendo inseticida
CO6592014A2 (es) Combinaciones que incluyen proteinas cry34ab/35ab y cry3aa para prevenir el desarrollo de resistencia en gusanos de la raíz maíz (diabrotica spp)
EA201791922A1 (ru) Композиции и способы для борьбы с насекомыми-вредителями
CL2012002311A1 (es) Compuestos derivados de dihidrofurano, o una sal o n-óxido del mismo, útiles como insecticidas; métodos para el control se insectos, acarinos, nemátodos o moluscos que lo comprenden; producto de combinación que comprende un derivado de dihidrofurano y un pesticida.
AU2018261075A1 (en) RNAi approach for crop pest protection
AR111256A1 (es) Combinaciones de yersinia entomofaga y pesticidas u otras sustancias
BR112018000802B8 (pt) Sistema de controle e/ou detecção de praga
BR112018003695A2 (pt) proteínas inibidoras de inseto
BR112019007180A2 (pt) proteínas inibidoras inseticidas
BR112022012269A2 (pt) Derivados de isoxazolina como pesticidas
CO2022018332A2 (es) Un sistema de estabilización para una composición agroquímica
CO2017008569A2 (es) Formulaciones pesticidas de compuestos orgánicos no volátiles
MX2020000581A (es) Sistema para liberar acaros beneficiosos y usos del mismo.
MX2019011192A (es) Metodo para criar y seleccionar pupas de encarsia formosa y amitus fuscipennis y metodo para controlar la mosca blanca en cultivos de tomate de invernadero.
CY1121397T1 (el) Μαλακιοκτονος συνθεση
PH12018502459A1 (en) Formulations containing volatile insecticides, with improved long term stability and effectiveness
MX2017003657A (es) Composicion pesticida.